OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

HTML

Year: 2013
Type: article
Source: Cancer Chemotherapy and Pharmacology
DOI: 10.1007/s00280-013-2307-6
Authors: Kohei Motoshima, Yoichi Nakamura, Kazumi Sano, Yoji Ikegami, Takaya Ikeda, Kosuke Mizoguchi, Shinnosuke Takemoto, Minoru Fukuda, Seiji Nagashima, Tetsuya Iida, Kazuhiro Tsukamoto, Shigeru Kohno
Institutions: Nagasaki University, Meiji Pharmaceutical University, Japanese Red Cross Nagasaki Genbaku Hospital
Language: English

Topic: Lung Cancer Treatments and Mutations
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: erlotinib, non-small cell lung cancer, EGFR mutation, pharmacokinetics, trough concentration, objective response rate, progression-free survival, predictive biomarkers, EGFR tyrosine kinase inhibitors, rash, pneumonitis
SDG: Good health and well-being

Open Access status: green
OpenAlex ID: W1974635653
FWCI: 1.61
Cites: 21
Cited by: 14
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security